This month's Brain Capital event aimed to position Houston and Texas as global leaders in the brain economy space. Photo via Getty Images

Brain Capital: The New Competitive Edge in a Shifting Economy, a two-day meeting held at the TMC3 Collaborative Building on May 21-22, brought together global business and policy leaders to advance brain health initiatives. The event concluded with the announcement of Texas-focused strategies that will be presented at the G7 Summit in Calgary this June, aiming to position the state as a leading hub for brain health research.

According to an analysis by the McKinsey Health Institute, investing in brain health interventions has the potential to generate a $260 billion boost to Texas’ GDP. Brain health conditions are responsible for more than $1 trillion in lost productivity globally, and the costs are expected to increase to nearly $16 trillion by 2030, according to organizers of the event.

The Texas Legislature recently passed legislation to establish the Dementia Prevention Research Institute of Texas (DPRIT), which includes a $3 billion investment over 10 years. Leaders at the Brain Capital event announced the launch of an advocacy campaign to foster support for DPRIT, which will appear as a November 2025 ballot measure.

“Our work to deliver better brain health to Texas and the world is only just beginning,” Dr. Jochen Reiser, president of The University of Texas Medical Branch (UTMB) and CEO of the UTMB Health System, said in a news release. “Investing in brain capital means protecting our cognitive health, boosting economic growth and securing a future-ready workforce – goals that we believe Texans will rally behind.”

Additionally, the Center for Houston’s Future also announced its goal to make the brain economy a key part of its new plan for the Houston region, called Vision 2050. The Center for Houston’s Future’s goal is to position Houston to become the global leader in the brain economy space, which will serve as a blueprint for other cities

“Houston has a clear track record leading the transition of industry sectors,” David Gow, CEO of the Center for Houston’s Future, said in a news release. “By launching a focused Brain Economy transition plan, Houston can integrate neuroscience, prevention, workforce resilience and cognitive innovation across sectors – preparing businesses and communities for an AI-driven future. Houston has the talent, infrastructure and vision to lead the nation in the next great economic transformation.”

Gow is the founder and chairman of Gow Media, InnovationMap's parent company.

Speakers at the event included executives from Shell Oil Co., scientists from Johns Hopkins Bloomberg School of Public Health, professors from Rice University, representatives from D.C.-based UsAgainstAlzheimer’s, and others. Learn more here.

Don't miss these February events — from talks with the hall-of-fame beauty business founders to AI summits. Photo courtesy of Rice University

10+ can't-miss Houston business and innovation events for February

WHERE TO BE

From talks with the hall-of-fame beauty business founders to agtech and AI summits, Houston will host a number of events focused on innovation and innovators in February.

Here’s what not to miss and how to register.

Note: This post might be updated to add more events.

Feb. 7 – SheSpace Offsite: Coffee & Connection

Get out of the office and head over to Midtown network with fellow SheSpace members and working women via coffee and conversation.

This event is Friday, Feb. 7, from 2-4 p.m. at Kefita Coffee. RSVP here.

Feb. 11 – Texas Business Hall of Fame x Ion: Creators Series with Founders Janet Gurwitch (Laura Mercier) and Tiffany Masterson (Drunk Elephant)

Take part in Texas Business Hall of Fame’s launch of its Creators 2025 speaker series. Janet Gurwitch, founder of Laura Mercier, and Tiffany Masterson, founder of Drunk Elephant, will discuss lessons learned while building their global retail brands and their successful exits.

This event is Tuesday, Feb. 11, from 8–10 a.m. at the Ion. Register here.

Feb. 11 – How to Start a Startup

Gain insight from Mercury Fund’s Heath Butler and stick around for a happy hour afterward. This session, originally scheduled for Jan. 21, is geared toward entrepreneurs, small business owners, investors and academic partners

This event is Tuesday, Feb. 11, from 5:30–7 p.m. at the Ion. Register here.

Feb. 15 – Ion Family Tech Day: Youth Entrepreneurship with Lemonade Day University

Bring the whole family out to the Ion for a family-friendly entrepreneurial workshop with Lemonade Day. Kids can compete in a pitch competition to win free supplies, and trained instructors will coach kids on how to set goals, develop a business or marketing plan and budget, create a brand, save and invest money, and more.

This event is Saturday, Feb. 15, from 10 a.m.–12:30 p.m. at the Ion. Register here.

Feb. 18 — Female Founders and Friends

Connect with like-minded female founders, funders, and allies at this recurring event. Female Founders & Friends is open to all industries and coffee is provided.

This event is Tuesday, Feb. 18, at 9 a.m. at Sesh Coworking. Register here.

Feb. 20 — Diaspora Africa Conference

Come together to hear inspiring speakers, participate in interactive workshops and network with others who are passionate about African heritage and the contributions of the African diaspora. This event will showcase African innovation and allow attendees to connect with funding sources actively seeking high-growth opportunities in Africa.

This event is Thursday, Feb. 20, from 9 a.m.–6 p.m. at the Ion. Register here.

Feb 20–21 — TMC AI Summit 2025

The TMC AI Summit aims to translate advanced AI innovations into practical solutions for real-world biomedical and health care challenges by bringing together researchers, clinicians, and industry leaders. The event features various workshops and tracks with keynote speakers from Rice University, UTHealth, Microsoft Health Futures and other organizations.

This event is Thursday, Feb. 20, from noon–7 p.m. and Friday, Feb. 21, from 8 a.m.–5 p.m. at TMC Helix Park in the TMC3 Collaborative Building. Register here.

Feb. 25 — Houston Methodist Leadership Speaker Series at Ion - Tesha Montgomery

Hear from Houston Methodist’s SVP of System Patient Access about how the health care system is approaching improvements to patient access and highlighting women in health care leadership. Audiences can participate in a 30-minute discussion following Montgomery’s remarks.

This event is Tuesday, Feb. 25, from 4:45–6 p.m. at the Houston Methodist Tech Hub at the Ion. Register here.

Feb. 26 — Inaugural HTX AgTech Rodeo Innovation Summit 2025

Network with farmers, founders, startups and investors at the first-ever HTX AgTech Rodeo Innovation Summit. The all-day event will feature panels, fireside chats, a Saddle Up Pitch Competition and reception with live music.

This event is Wednesday, Feb. 26, from 8:30 a.m.–8 p.m. Find more information and register here.

Feb. 27 — NASA Tech Talks

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.


This event is Thursday, Feb. 27, from 6-7 p.m. at the Ion. Register here.

Feb. 27–28 – QVIDTVM x The Ion: Inaugural Hack Day Competition

Investment firm QVIDTVM and the Ion are calling all data scientists, analysts, developers and innovators to a new hack day. Participants will aim to find the total value of real estate platformed by Airbnb globally and can participate in a Fireside Chat on AI with Nick King, founder and CEO of Data Kinetic. Teams can include up to four people and prizes for first through third place will be awarded.

This event is Thursday, Feb. 27, at 9:30 a.m. until Friday, Feb. 28, at 5 p.m. at the Ion. Register here.


Portal Innovations announced that Monique Knighten as an executive director in Houston. Photo via LinkedIn

Chicago life science innovation firm names Houston leader

who's who

After announcing its expansion into Houston last summer and opening its office in a new Texas Medical Center building, Portal Innovations has named its Houston leader.

Portal Innovations announced that Monique Knighten as an executive director in Houston in a LinkedIn post this week. She has over 15 years of experience in supporting research scientists and clinicians working to develop therapeutics in labs and clinics. According to her LinkedIn, she's served in the position since November.

Prior to her new role at Portal, Knighten worked as a manager level at Sartorius Stedim in Houston for five years. Before that role, she served as a technical sales consultant in Texas at Miltenyi Biotec, primarily in the immuno-oncology therapeutic market in the TMC.

Portal first announced its expansion into Houston in June of last year.

“Houston is one of the fastest-growing cities in the U.S., and home to one of the world’s leading cancer research institutions, The University of Texas MD Anderson Cancer Center,” Portal’s Founder and CEO John Flavin said at the time. “It’s critical for us to open in Texas and leverage nearby pipelines from Rice University, UTHealth Houston, Texas A&M, University of Houston, Baylor College of Medicine, and others across Houston’s innovative life sciences ecosystem. We’re thrilled to work with TMC to help grow tomorrow’s biotech and medtech leaders.”

Portal's local office is in the Helix Park complex's Collaborative Building, which opened in October. Helix Park is a 37-acre mixed-use campus currently under construction. The institutional agnostic, 250,000-square-foot building will anchor Helix Park and house research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

Mayor Sylvester Turner, TMC CEO Bill McKeon, Governor Greg Abbott, and others gave their remarks at the TMC3 Collaborative Building opening. Photo by Natalie Harms

Texas Medical Center opens first building in massive Helix Park project

tmc3

For nearly a decade, the Texas Medical Center and its partners have been working on the plans for Helix Park, a 37-acre campus expansion of TMC. As of this week, the first building has opened its doors to the public.

The TMC3 Collaborative Building officially opened today to a crowd of media, public officials, and health care executives. The institutional agnostic, 250,000-square-foot building will anchor Helix Park and house research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

“Today, we lay the cornerstone of a new campus fully dedicated to streamlining the commercialization of life-changing innovations in medicine and technologies,” William McKeon, president and CEO of TMC, says at the event. “We are incredibly excited to both welcome our founding institutions and industry partners to the Collaborative Building and to invite the community to experience the Helix Park campus and its beautiful parks with a series of special events in the months ahead."

Established to be a place for academic institution collaboration, the building — designed by Boston-based Elkus Manfredi Architects — will have wet laboratories, office space, and event facilities. Two venture groups — Portal Innovations and the TMC Venture Fund — will also move into the building.

Each institution will bring in select programs and initiatives. MD Anderson will house two institutions within the new building, including the James P. Allison Institute focused on immunotherapy and the Institute for Data Science in Oncology.

"The future of life sciences in Houston is brighter than ever before as we come together to officially open the TMC3 Collaborative Building,” Dr. Peter WT Pisters, president of MD Anderson, says. “Our clinicians and scientists work daily to advance innovations in cancer research and care – all of which will be amplified in this new environment within Helix Park that further cultivates collaboration, connectivity, and creativity.”

UTHealth will move its Texas Therapeutics Institute into the facility.

“With a shared commitment to improving the health and well-being of individuals and communities, we are bringing together academics and industry to accelerate discovery and medical breakthroughs,” Dr. Giuseppe N. Colasurdo, president and Alkek-Williams Distinguished Chair at UTHealth Houston, says. “Through the Texas Therapeutics Institute — already a signature collaborative enterprise at UTHealth Houston — our world-renowned leaders in therapeutic antibody development will have the opportunity to work closely with other leading researchers in the Texas Medical Center, greatly enhancing our collective ability to translate discoveries and ideas into effective treatments.”

Texas A&M, which has worked with Houston Methodist to develop its engineering medical program, will operate its Texas A&M Health’s Institute of Biosciences and Technology in the new space.

“As we open this state-of-the-art facility, we’re opening the door to a new era of collaboration. This building signifies the dismantling of silos to deliver game-changing therapies for the toughest diseases impacting Texans and citizens worldwide,” said John Sharp, Chancellor of The Texas A&M University System. “Texas A&M Health’s Institute of Biosciences and Technology has long been a trailblazer in drug discovery, and now, in the heart of this resource-rich ecosystem of the Texas Medical Center, we’re taking it up a notch. By positioning our scientists near their peers and esteemed clinicians, we’re igniting a spark that will fuel innovation and forge dynamic research programs.”

The next aspect of Helix Park to deliver will be the Dynamic One, a 700,000-square-foot industry research facility. Several other buildings, including a hotel, residential tower, and mixed-use building, are expected to deliver over the next few years. The "spine" of the project is six linked green spaces, designed by landscape architect Mikyoung Kim, that form an 18.7-acre campus, which is shaped like a DNA helix, hence the project's name.

At the opening event, leaders discussed the annual impact of over $5.4 billion expected after the campus is completed, and the 23,000 permanent new jobs and 19,000 construction jobs anticipated from Helix Park.

"Texas truly is the home of innovation. Our energy innovations are legendary, as are our innovations in space," says Texas Governor Greg Abbott, naming several of the state's innovative accomplishments. "Long before all of this innovation we're seeing now, Texas was the home of the Texas Medical Center."

Mayor Sylvester Turner spoke to the importance of collaboration.

"Individually, you can do things very well. Collectively, you can be transformational," he says. "One thing about this city, collaboration is the key. When we play well together, and when we build an integrated, robust ecosystem, everyone wins. That's Houston, and that's the way we operate."

The Dynamic One building in TMC Helix Park is expected to deliver later this year. Rendering via TMC.edu

Rising TMC development names Houston health care institution as anchor tenant

coming soon

TMC Helix Park, formerly known as TMC3, has announced its first anchor tenant.

The Texas Medical Center and Beacon Capital Partners announced that Baylor College of Medicine will be the anchor tenant of the Dynamic One building at TMC Helix Park. The facility is will be the first to deliver of the four TMC Helix Park industry buildings. The Topped off in December, the Dynamic One building is being developed by Beacon in collaboration with Zoë Life Science and is scheduled to open before the end of the year.

“Beacon is excited that Dynamic One will be our first entry into the fast-growing Houston Life Science market,” says Fred Seigel, president and CEO of Beacon, in a news release. “This state-of-the-art environment is designed to enable and encourage collaboration and will greatly accelerate the innovative lifesaving discoveries that emerge when industry and academic research work side-by-side.”

Baylor College of Medicine will lease 114,000 square-feet of lab and office space in the 355,000-square-foot building. BCM's goal is to house lab space for novel diagnostics and therapeutics — and provide space to house startups.

The organization is expanding its presence in Houston after decades of residing in the region.

“Baylor College of Medicine moved to Houston in 1943 and was the first institution built in the Texas Medical Center," says Dr. Paul Klotman, president and CEO and executive dean of Baylor, in the release. "Our researchers and scientists will have the opportunity to access the uniquely concentrated research environment being developed at TMC Helix Park, facilitating the continuing advancement of innovation and compassionate care."

TMC Helix Park, which includes more than 5 million-square-feet of space across 37-acres, also expects to deliver its research facility, the TMC3 Collaborative Building, later this year.

“Baylor College of Medicine is a major force in life sciences discovery and commercialization at TMC," says Bill McKeon, president and CEO of TMC, in the release. "Their move to TMC Helix Park will serve as a catalyst for enhanced collaboration with TMC’s other esteemed Institutions, as well as with industry leaders from around the world."

BCM is the first anchor tenant announced for TMC Helix Park. Rendering via TMC.edu

A TMC construction update, a Q&A with UH's med school donor, and other top health tech stories of 2022. Image courtesy of Elkus Manfredi Architects

Here are Houston's top health tech innovation stories of the year

2022 in review

Editor's note: As 2022 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. In Houston, home to the world's largest medical center, health tech and innovation news is abound — from startups being named among the most promising by investors to new details on the Texas Medical Center's expansion. Here are five Houston health tech-focused articles that stood out to readers this year — be sure to click through to read the full story.


Houston organizations announce 10 most promising life science startups

Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

What startups are creating the future of health care? A Houston conference this week gathered to discuss.

The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. Read more.

Houston hospital system to open new innovative location

Houston Methodist broke ground on a 400-bed hospital in Cypress. Rendering courtesy of Houston Methodist

Houston Methodist will soon break ground on a “smart” hospital in Cypress that is poised to be the smartest of its nine hospitals.

The $650 million Cypress hospital will be modeled after Houston Methodist West and Houston Methodist The Woodlands hospitals. However, the Cypress location is on track to outdo them in terms of smart technology.

“Our commitment to innovation is one more way we set ourselves apart from other hospital systems, and we are committed to making this new hospital the most technologically advanced and innovative hospital ever,” Dr. Marc Boom, president and CEO of Houston Methodist, says in a note to employees. Read more.

Following $50M gift,Tilman Fertitta reveals goals for eponymous medical school at University of Houston

Fertitta and his family have gifted $50 million to UH's medical school. Photo courtesy

As Houston’s most high-profile billionaire and owner of the posh 5-star Post Oak Hotel and Houston Rockets, Tilman J. Fertitta has become synonymous with over-the-top opulence and big-time entertainment.

But the CEO of the massive Feritta Entertainment empire’s latest move has nothing to do with penthouses or point guards, but rather a legacy, game-changing appropriation meant to aid his home state’s health.

The longtime UH board member and former chairman and his family have just pledged $50 million to the University of Houston College of Medicine. In turn, the new medical school has been christened the Tilman J. Fertitta Family College of Medicine. Read more.

TMC unveils details of new bioport, Helix Park at annual Greater Houston Partnership event

TMC gave an update on TMC3 — now called TMC Helix Park — and introduced a new bioport project. Courtesy of Elkus Manfredi Architects

Within the next five to 10 years, the Texas Medical Center you know today will be double the size. That's what Bill McKeon, president and CEO of the TMC, said at yesterday's State of the Texas Medical Center event hosted by the Greater Houston Partnership.

The biggest project contributing to the TMC's growth is TMC3, a campus expansion that will bring 37 acres and 5 million square feet of space to the TMC, is now known as Helix Park. The name is a nod to the shape of the park and walkway design at the center of the campus. The TMC3 Collaborative Building — the first multi-institutional research facility in TMC’s history — will be the first of the project to deliver and is currently under construction and slated for completion in 2023.

However, the big news of the event was the TMC BioPort, the organization's upcoming biomanufacturing and medical supplies distribution engine. This new campus will span several hundred acres just down the road from TMC and will drive the much-needed repatriation of critical medical supplies and new cell and gene therapies, per a news release. Read more.

Overheard: Houston experts discuss women in med tech, insight from investors, and more

Health care innovators joined Houston Methodist and Texas A&M University's ENMED program to discuss women in health care innovation and venture capital investment. Photo courtesy of Houston Methodist

Houston's health innovation community is making strides every day toward greater quality of care and technology adoption — but what challenges is the industry facing these days?

Through a partnership between Houston Methodist and Texas A&M University's ENMED program at Houston Tech Rodeo, health innovators weighed in on topics surrounding the industry, including biases and investment opportunities.

Missed the conversation? Here are seven key moments from the panels that took place at A&M's new ENMED building in the Texas Medical Center on Thursday, March 3. Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.